ureteral stent
Recently Published Documents


TOTAL DOCUMENTS

1030
(FIVE YEARS 318)

H-INDEX

40
(FIVE YEARS 4)

2022 ◽  
Vol 10 (3) ◽  
pp. 802-810
Author(s):  
Mao-Mao He ◽  
Xiao-Ting Lin ◽  
Ming Lei ◽  
Xiao-Lan Xu ◽  
Zhi-Hui He

2022 ◽  
Vol 48 (1) ◽  
pp. 30-40
Author(s):  
Anak Agung Ngurah Oka Diatmika ◽  
Tarmono Djojodimedjo ◽  
Yudhistira Pradnyan Kloping ◽  
Furqan Hidayatullah ◽  
Mohammad Ayodhia Soebadi

2022 ◽  
Author(s):  
Nicholas Alexander Pickersgill ◽  
B. Malik Wahba ◽  
Joel M. Vetter ◽  
Sky Jin Cope ◽  
Nimrod Shabtai Barashi ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S397
Author(s):  
Morgan Scaglione ◽  
Amanda A. Allshouse ◽  
Dana R. Canfield ◽  
Ann M. Bruno ◽  
Ibrahim Hammad ◽  
...  

2021 ◽  
Vol 16 (3) ◽  
pp. 61-66
Author(s):  
Useok Choi ◽  
Eun Jae Kim ◽  
Don Hee Lyu ◽  
Bong Hee Park ◽  
Hong Chung ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Xiaoshuai Gao ◽  
Jixiang Chen ◽  
Zhongyu Jian ◽  
Menghua Wang ◽  
Wei Wang ◽  
...  

Background: The aim of this prospective study was to assess the safety and effectiveness of self-expanding metal ureteral stent (MUS) for the treatment of recurrent ureteral stricture after ureteroplasty.Methods: We prospectively included 24 patients who underwent MUS implantation between February 2019 and August 2020. The inclusion criteria for the procedure were recurrent ureteral strictures after ureteroplasty. A paired T test was used to compare continuous variables before and after surgery.Results: A total of 24 patients were finally included in this study. The stricture site was most common on the proximal ureter 19 (79.2%), followed by distal ureter 4 (16.7%) and middle ureter 1 (4.2%). The median length of ureteral stricture is 2.5 (range 1–18) cm. The median operative time was 51.5 min, and the median hospital stay time after surgery was 3 days. Post-operative complication included pain 1 (4.2%), urinary tract infection 2 (8.3%) and hematuria 2 (8.3%). After a median follow-up of 12 months, 19/24 (83.3%) patients were clinically and radiologically successful. We endoscopically adjusted or exchanged the failed stents. The volume of hydronephrosis (124.7 ± 132.5 vs. 66.4 ± 73.2 cm3, P = 0.015), blood creatinine level (104.5 ± 45.4 vs. 80.1 ± 23.2 μmol/L, P = 0.044) and urea nitrogen level (6.9 ± 2.4 vs. 4.8 ± 1.5 mmol/L, P = 0.003) decreased significantly after a median follow-up of 12 months.Conclusions: MUS is a safe and effective way to manage recurrent ureteral strictures after ureteroplasty. This technique provides a new choice for the treatment of recurrent stricture.


2021 ◽  
Vol 42 (2) ◽  
pp. 160-168
Author(s):  
Tongtra Watcharawittayakul ◽  
◽  
Manint Usawachintachit ◽  

Ureteral stent insertion is a procedure performed extensively by all urologists. Nevertheless, stent-related symptoms and stent encrustation are still common complications pushing the innovation and development of novel ureteral stents. Developments are focussing on three significant aspects: material, design, and removal technique. Various materials including silicone, polymers, and metals are frequently utilized, with or without an additional coating. The use of biodegradable materials is looking promising but these is a lack of proven clinical trials in association with this in humans. The new designs focus on the reduction of stent-related symptoms through the modification of the bladder end. The new stent removal techniques with extraction strings or novel magnetic end may exclude subsequent cystoscopic procedures. Finally, utilization of a ureteral stent tracker application helps in reminding both physicians and patients to remove the stent at the appropriate time.


2021 ◽  
Vol 67 (12) ◽  
pp. 1793-1797
Author(s):  
Paulo Jaworski ◽  
Gregório Fadel Mello ◽  
Guilherme Monteiro Ferreira ◽  
Maria Helena Oliveira ◽  
Rogerio de Fraga
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document